New York Times Co vs uniQure N.V. Ordinary Shares — how do they compare? New York Times Co trades at $67.13 (market cap $10.79B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: New York Times Co is far larger — about 7.3× uniQure N.V. Ordinary Shares's market cap, and New York Times Co pays a 1.38% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NYT | QURE | |
|---|---|---|
Market Cap | $10.79B | $1.48B |
Volume | 2,034,872 | 2,488,780 |
Sector | Media | Health |
52-Week High | $85.86 | $70.59 |
52-Week Low | $54.86 | $9.03 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $10.18B | $728.62M |
Dividend Yield | 1.38% | — |
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.15, up 1.62% on the day, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82 billion in 2025, with net income reaching $344 million and a 12.17% margin. The company has beaten earnings estimates for the last three quarters, and analysts set a consensus price target of $81.50. Recent news includes a dividend declaration and ongoing litigation related to AI copyright issues.
Outlook is mixed: solid earnings growth and profitability support upside, but technical indicators and a shareholder lawsuit pose near-term risks. The stock offers value if it can maintain its growth trajectory, though investors should monitor legal developments and market sentiment closely.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →